PRESS RELEASE published on 06/18/2025 at 06:25, 1 year 4 months ago Formycon AG: Subscription period for 2025/2029 corporate bond has started Formycon AG announces the start of the subscription period for the 2025/2029 corporate bond with a target volume of EUR 50 million, featuring a variable interest rate. Investors can submit subscription offers until June 27, 2025 Growth Strategy Formycon AG Interest Rate Corporate Bond Subscription Period
PRESS RELEASE published on 06/18/2025 at 06:14, 1 year 4 months ago EQS-Adhoc: Airbus to present new dividend policy and reaffirm cash conversion target during business update on 18 June 2025 Airbus SE to present new dividend policy and reaffirm cash conversion target during business update on June 18, 2025. Strengthening commitment to increasing shareholder returns Business Update Dividend Policy Airbus SE Shareholder Returns Cash Conversion Target
PRESS RELEASE published on 06/18/2025 at 05:58, 1 year 4 months ago Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals Lobe Sciences Ltd. advances Conjugated Psilocin™ research for chronic cluster headaches and addiction via $6M investment in Cynaptec Pharmaceuticals, with option for additional $20M Clinical Trials Investment Cynaptec Pharmaceuticals Lobe Sciences Ltd. Conjugated Psilocin™
PRESS RELEASE published on 06/17/2025 at 23:00, 1 year 4 months ago New to The Street Signs Backstage ($ BKS) to 12-Part Media Series Covering Music, Sports, and Tokenized Real-World Assets in Entertainment New to The Street announces exclusive media series with Backstage (NASDAQ:BKS) for mainstream adoption of tokenized entertainment. Campaign includes TV, billboards, and editorial support New To The Street Media Series Backstage Tokenized Entertainment Mainstream Adoption
PRESS RELEASE published on 06/17/2025 at 23:00, 1 year 4 months ago Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy Medicure Inc. announces acquisition of West Olympia Pharmacy Inc., further boosting direct-to-consumer pharmacy business and sales of ZYPITAMAG(R) and BRENZAVVY(R) Acquisition Medicure Inc. Pharmacy Business ZYPITAMAG(R) BRENZAVVY(R)
PRESS RELEASE published on 06/17/2025 at 22:50, 1 year 4 months ago EQS-Adhoc: Verve Group SE: Verve successfully completes a directed share issue of 12,858,000 new shares raising proceeds of approximately SEK 360 million Verve Group SE successfully completes a directed share issue of 12,858,000 new shares raising proceeds of approximately SEK 360 million. The subscription price is SEK 28.00 per share Market Conditions Subscription Price Verve Group SE Directed Share Issue SEK 360 Million
PRESS RELEASE published on 06/17/2025 at 22:50, 1 year 4 months ago Verve Group SE (Nordic): Verve successfully completes a directed share issue of 12,858,000 new shares raising proceeds of approximately SEK 360 million Verve Group SE completes directed share issue of 12,858,000 new shares, raising SEK 360 million. Key investors include industry experts. Proceeds to fund growth initiatives and strengthen balance sheet Investor Base Share Issue Verve Group SE Directed Share Issue SEK 360 Million
PRESS RELEASE published on 06/17/2025 at 22:10, 1 year 4 months ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
PRESS RELEASE published on 06/17/2025 at 20:30, 1 year 4 months ago GENFIT: June 17, 2025 Combined Shareholders Meeting Results GENFIT announces approval of all resolutions at June 17, 2025 Combined Shareholders Meeting. Exception: resolution n°28 rejected. Quorum: 27.21% Resolutions Approval Quorum Shareholders Meeting GENFIT
PRESS RELEASE published on 06/17/2025 at 20:30, 1 year 4 months ago GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 GENFIT annonce les résultats de son Assemblée Générale Mixte du 17 juin 2025, approuvés avec un quorum de 27,21%, tout en dévoilant sa mission et activités dans le secteur biopharmaceutique Biopharmaceutique Assemblée Générale Mixte Maladies Rares GENFIT Foie
Published on 11/14/2026 at 12:56, 1 day ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 12 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 12 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 13 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 13 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 14 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 15 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 18 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 18 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days 2 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days 2 hours ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 5 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 14 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)